NICE recommends Novartis’ Kymriah CAR T-cell therapy for adults with lymphoma

AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access Novartis’ Kymriah CAR T-cell therapy through the Cancer Drugs Fund.

Tisagenlecleucel, also known as Kymriah and made by Novartis, is recommended for adults with relapsed or refractory DLBCL. It will be offered to people whose disease has not responded or those whose disease has relapsed after treatment with two or more courses of chemotherapy.

NICE’s initial draft guidance did not recommend tisagenlecleucel as the therapy was not considered cost-effective. Further negotiations between NHS England and the company led to a commercial agreement offering the therapy at a lower price. After considering the evidence, the committee concluded tisagenlecleucel for adults with large B-cell lymphoma, after two or more systemic therapies, can be offered through the Cancer Drugs Fund.

The list price for tisagenlecleucel is £282,000 and it is given as a single intravenous infusion. The company has agreed to offer the therapy at a confidential discounted price. It is estimated that 200 people will be eligible for treatment each year in the UK and NHS England is working closely with several hospitals across the country to deliver this complex treatment.

Lymphomas are cancers of the lymphatic system which is part of the immune system. There were 11,690 new cases of non-Hodgkin lymphoma in England in 2015 with 4,688 of these being diffuse large B-cell lymphoma.

Meindert Boysen, Director of the Centre for Health Technology Evaluation at NICE, said: “Recommending another revolutionary CAR T-cell therapy for adults with lymphoma represents a step forward for personalised medicine. We are pleased that patients are set to benefit from such an innovative therapy so rapidly because of joint working between NICE, NHS England and the company.

“CAR T-cell therapy is expensive, however the treatment is specific to each individual and could be a potential cure for some, although it is early days. Our recommendation for tisagenlecleucel on the Cancer Drugs Fund means people can benefit while more data is collected.”

Ropinder Gill, Lymphoma Action Chief Executive, said: “We’re very pleased that this ground-breaking CAR T-cell therapy will now be available on the NHS for some people with diffuse large B-cell lymphoma.  This is really good news for people affected by this type of lymphoma who, until now, have faced limited treatment options.  The news offers patients and their families faced with a poor prognosis a more hopeful outlook.”

John Stewart, Director of Specialised Commissioning at NHS England, said: “The NHS has agreed another deal with the manufacturer Novartis which means that from next week more patients will benefit from this game changing treatment at even more hospitals throughout the country.

“Providing the latest cutting edge treatments for patients through competitive drug deals and offering more personalised medicines like CAR T-cell therapy are just two of the ways that the NHS Long Term Plan will transform cancer care across the country.”

Dr Alasdair Rankin, Director of Research and Patient Experience at the blood cancer charity Bloodwise, said: “CAR T-cell therapy is the most promising breakthrough in blood cancer treatment of the past decade, with the potential to be used much more widely in the future.

“Ensuring access to CAR T-cell therapies gives these patients the real chance of long-term survival when all other treatments have failed.”

For more information on blood cancer, read Pf’s therapy article on the subject.